Factors predicting recurrence after resection of pancreatic ductal carcinoma

被引:59
作者
Shibata, K [1 ]
Matsumoto, T [1 ]
Yada, K [1 ]
Sasaki, A [1 ]
Ohta, M [1 ]
Kitano, S [1 ]
机构
[1] Oita Univ, Fac Med, Dept Surg 1, Oita 8795593, Japan
关键词
hepatic metastasis; invasion of the portal vein; pancreatic ductal carcinoma; peritoneal carcinomatosis; undifferentiated adenocarcinoma;
D O I
10.1097/01.mpa.0000166998.04266.88
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: Pancreatic ductal carcinoma frequently recurs postoperatively, and we analyzed clinicopathological features of patients treated by surgical resection to find predictors of postoperative recurrence. Methods: A retrospective cohort study was performed that included 69 patients between 1985 and 2003. Clinicopathologic factors were evaluated for tumor recurrences by univariate and multivariate analyses. Results: Mean survival time and actuarial 5-year disease-specific survival were significantly lower in cases of hepatic metastasis (13 months, 0%) and in cases of peritoneal carcinomatosis (15 months, 6.8%) than in cases of local retroperitoneal recurrence (30 months, 21%). Univariate and logistic regression analyses showed undifferentiated adenocarcinoma to be independently associated with hepatic metastasis (odds ratio, 7.4; 95% confidence interval, 1.5-37.0) and invasion of the portal vein to be independently associated with peritoneal carcinomatosis (odds ratio, 4.0; 95% confidence interval, 1.2-12.8). Multivariate analysis showed undifferentiated adenocarcinoma, invasion of the anterior capsule, and invasion of the portal vein to be independent prognostic factors. Conclusion: Undifferentiated adenocarcinoma and invasion of the portal vein are predictors of poor outcome and are related to hepatic metastasis and peritoneal carcinomatosis, respectively. Postoperative adjuvant chemotherapy, including intra-arterial chemotherapy, should be selected according to prediction of the patterns of recurrence.
引用
收藏
页码:69 / 73
页数:5
相关论文
共 30 条
[1]  
Ahmad NA, 2001, AM J GASTROENTEROL, V96, P2609
[2]  
Aramaki M, 2003, HEPATO-GASTROENTEROL, V50, P263
[3]   Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer:: Significant reduction in occurrence of liver metastasis [J].
Beger, HG ;
Gansauge, F ;
Büchler, MW ;
Link, KH .
WORLD JOURNAL OF SURGERY, 1999, 23 (09) :946-949
[4]   Extended lymphadenectomy and vein resection for pancreatic head cancer -: Outcomes and implications for therapy [J].
Capussotti, L ;
Massucco, P ;
Ribero, D ;
Viganò, L ;
Muratore, A ;
Calgaro, M .
ARCHIVES OF SURGERY, 2003, 138 (12) :1316-1322
[5]   Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors [J].
Cleary, SP ;
Gryfe, R ;
Guindi, M ;
Greig, P ;
Smith, L ;
Mackenzie, R ;
Strasberg, S ;
Hanna, S ;
Taylor, B ;
Langer, B ;
Gallinger, S .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (05) :722-731
[6]   Long-term survival after curative resection for pancreatic ductal adenocarcinoma - Clinicopathologic analysis of 5-year survivors [J].
Conlon, KC ;
Klimstra, DS ;
Brennan, MF .
ANNALS OF SURGERY, 1996, 223 (03) :273-279
[7]  
Crane Christopher H, 2003, Surg Oncol Clin N Am, V12, P965, DOI 10.1016/S1055-3207(03)00090-5
[8]   PROGNOSTIC INDICATORS FOR SURVIVAL AFTER RESECTION OF PANCREATIC ADENOCARCINOMA [J].
GEER, RJ ;
BRENNAN, MF .
AMERICAN JOURNAL OF SURGERY, 1993, 165 (01) :68-72
[9]  
Iacono C, 1999, J Hepatobiliary Pancreat Surg, V6, P74, DOI 10.1007/s005340050086
[10]   Extended pancreatectomy and liver perfusion chemotherapy for resectable adenocarcinoma of the pancreas [J].
Ishikawa, O ;
Ohhigashi, H ;
Sasaki, Y ;
Furukawa, H ;
Imaoka, S .
DIGESTION, 1999, 60 :135-138